Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Caner SayginPu ZhangJacob StauberIbrahim AldossAdam S SperlingLachelle Dawn WeeksMarlise R LuskinTodd C KnepperPankhuri WanjariPeng WangAngela M LagerCarrie FitzpatrickJeremy P SegalMehdi GharghabiSandeep K GurbuxaniGirish VenkataramanJason X ChengBartholomew J EisfelderOliver BohorquezAnand Ashwin PatelSheethal Umesh NagalakshmiSavita JayaramOlatoyosi M OdenikeRichard A LarsonLucy A GodleyDaniel A ArberChristopher J GibsonNikhil C MunshiGuido MarcucciBenjamin L EbertJohn M GreallyUlrich SteidlRosa LapalombellaBijal D ShahWendy StockPublished in: Blood cancer discovery (2024)
CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142.